These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35996404)

  • 1. Erratum to "Evaluation of the Mechanism of Modified Lingguizhugan Decoction in the Treatment of Nonalcoholic Fatty Liver Disease".
    Yang F; Zhou J; Su B; Zhang Q; Luo X; Wang F; Huang J; Huang W
    Evid Based Complement Alternat Med; 2022; 2022():9782896. PubMed ID: 35996404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Mechanism of Modified Lingguizhugan Decoction in the Treatment of Nonalcoholic Fatty Liver Disease.
    Yang F; Zhou J; Su B; Zhang Q; Luo X; Wang F; Huang J; Huang W
    Evid Based Complement Alternat Med; 2022; 2022():4576679. PubMed ID: 35116066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of Lingguizhugan decoction on amyloid-beta peptide (25-35)-induced cell injury: Anti-inflammatory effects.
    Xi F; Sang F; Zhou C; Ling Y
    Neural Regen Res; 2012 Dec; 7(36):2867-73. PubMed ID: 25317138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effects of Lingguizhugan decoction in the treatment of hypertension: a systematic review and meta-analysis.
    Xie P; Li X; Jiang H; Qiu S; Liang Y
    Ann Palliat Med; 2021 Nov; 10(11):11529-11538. PubMed ID: 34872278
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Zhu M; Hao S; Liu T; Yang L; Zheng P; Zhang L; Ji G
    Oncotarget; 2017 Oct; 8(47):82621-82631. PubMed ID: 29137289
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Yang L; Lin W; Nugent CA; Hao S; Song H; Liu T; Zheng P
    Int J Genomics; 2017; 2017():2790864. PubMed ID: 29464180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified lingguizhugan decoction incorporated with dietary restriction and exercise ameliorates hyperglycemia, hyperlipidemia and hypertension in a rat model of the metabolic syndrome.
    Yao L; Wei J; Shi S; Guo K; Wang X; Wang Q; Chen D; Li W
    BMC Complement Altern Med; 2017 Feb; 17(1):132. PubMed ID: 28241808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erratum: Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia: Erratum.
    Medicine (Baltimore); 2017 Jun; 96(23):e7231. PubMed ID: 31305674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lingguizhugan Decoction Targets Intestinal Microbiota and Metabolites to Reduce Insulin Resistance in High-Fat Diet Rats.
    Ning Y; Gong Y; Zheng T; Xie Y; Yuan S; Ding W
    Diabetes Metab Syndr Obes; 2022; 15():2427-2442. PubMed ID: 35971521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lingguizhugan decoction attenuates diet-induced obesity and hepatosteatosis
    Liu MT; Huang YJ; Zhang TY; Tan LB; Lu XF; Qin J
    World J Gastroenterol; 2019 Jul; 25(27):3590-3606. PubMed ID: 31367159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Traditional Chinese medicine Lingguizhugan decoction ameliorate HFD-induced hepatic-lipid deposition in mice by inhibiting STING-mediated inflammation in macrophages.
    Cao L; Xu E; Zheng R; Zhangchen Z; Zhong R; Huang F; Ye J; Sun H; Fan Y; Xie S; Chen Y; Xu Y; Cao J; Cao W; Liu C
    Chin Med; 2022 Jan; 17(1):7. PubMed ID: 34983596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erratum: Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
    Saudi J Gastroenterol; 2018; 24(4):255. PubMed ID: 30052239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erratum: Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling.
    Giles DA; Moreno-Fernandez ME; Stankiewicz TE; Graspeuntner S; Cappelletti M; Wu D; Mukherjee R; Chan CC; Lawson MJ; Klarquist J; Sünderhauf A; Softic S; Kahn CR; Stemmer K; Iwakura Y; Aronow BJ; Karns R; Steinbrecher KA; Karp CL; Sheridan R; Shanmukhappa SK; Reynaud D; Haslam DB; Sina C; Rupp J; Hogan SP; Divanovic S
    Nat Med; 2017 Oct; 23(10):1241. PubMed ID: 28985207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erratum: Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice [Corrigendum].
    Diabetes Metab Syndr Obes; 2023; 16():2833-2834. PubMed ID: 37736329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erratum: Sex-Based Differences and Risk Factors for Comorbid Nonalcoholic Fatty Liver Disease in Patients with Bipolar Disorder: A Cross-Sectional Retrospective Study [Corrigendum].
    Diabetes Metab Syndr Obes; 2024; 17():1335-1336. PubMed ID: 38525160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erratum to study on the mechanism of the Modified Ginseng-Schisandra Decoction (MGSD) in the treatment of recurrent respiratory tract infection (RRTI) based on network pharmacology.
    Editorial Office
    Transl Pediatr; 2021 Sep; 10(9):2408. PubMed ID: 34733683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chinese medicine formula lingguizhugan decoction improves Beta-oxidation and metabolism of Fatty Acid in high-fat-diet-induced rat model of Fatty liver disease.
    Liu T; Yang LL; Zou L; Li DF; Wen HZ; Zheng PY; Xing LJ; Song HY; Tang XD; Ji G
    Evid Based Complement Alternat Med; 2013; 2013():429738. PubMed ID: 23762134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erratum: Medicine, Volume 95, Issue 24: Erratum.
    Medicine (Baltimore); 2016 Aug; 95(31):e5074. PubMed ID: 31265618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erratum: Medicine, Volume 95, Issue 23: Erratum.
    Medicine (Baltimore); 2016 Jul; 95(28):e0916. PubMed ID: 31265603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of bariatric surgeries on nonalcoholic fatty liver disease: Erratum.
    Saudi J Gastroenterol; 2015; 21(5):341. PubMed ID: 26458864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.